GLP1R and diabetes mellitus: The American Diabetes Association recently issued a statement recommending against using non–FDA-approved compounded GLP-1 and dual GIP/GLP-1 receptor agonist products due to safety, quality, effectiveness concerns, and uncertainty about their content [13].